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Background: Despite marijuana is the most frequent drug use worldwide,
there is no prospective clinical data of its implication in acute coronary syn-
dromes (ACS). The aim of this study was to evaluate the prevalence of mari-
juana smokers in young people admitted to intensive unit care for ACS.
Material and Methods: From September 2010 to Mars 2011, we prospec-
tively included all patients below 50 years old admitted for ACS at the University
Hospital of Toulouse, France and assessed their use of Marijuana by medical ques-
tioning and systematic urinary assay. Patients were divided into 2 groups (mari-
juana smokers and no marijuana smokers) according to the presence of marijuana
in urines. Parametric and non-parametric tests were used for groups comparison.
Results: 63 patients were included. Mean age was 42±7 years old and 52
(82.5%) patients were male. In this cohort, 23.8% (15) were recognized as
marijuana smokers (MS). There was no difference in classical cardiovascular
risk factors, age and gender between the two groups. Interestingly, MS present
significative more non ST elevation myocardial infarction than non MS
patients (67% vs 29.2%; p=0.009). There was no difference in the coronary
status but a high frequency of multivessel coronary disease (respectively
46.6% and 45.8%, p=0.95) in the two groups. There was no death in MS
group whereas two in the non MS group. No difference was observed in left
ejection fraction at hospital discharge (55% vs 52%, p=0.291). Marijuana
addiction is characterized by an 86.7% use in the 24 hours preceding the ACS
and 73.3% in the last three hours. 
Conclusion: Marijuana use is frequent, especially in the few hours preceding the
event, and probably underdiagnosed in ACS of people below 50 years old. Clinical
presentation of ACS is different in this group with less ST elevation suggesting a
more complex coronary artery disease. Multicentric study should be achieved to
assess epidemiology and pathophysiolgical role of marijuana use in ACS. 
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Clinical, angiographic and genetic determinants of early coronary stent
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Objectives: To perform a comprehensive analysis of all determinants of
definite early stent thrombosis (ST) to identify the risk and the modifiable fac-
tors of early ST.
Methods: Using a web-based case collection and reporting system,
123 patients with definite EST on dual antiplatelet therapy were matched 2:1
according to age and gender with 246 controls. All patients were genotyped
for 23 genetic variants involved in clopidogrel metabolism (CYP2C19,
CYP2C9, CYP2B6, CYP3A5, POR, ABCB1, PON1), platelet receptor func-
tion (P2Y12, ITGB3), and the coagulation and fibrinolytic system (MTHFR,
Factor V, Fibrinogen, Prothrombin, PAI1 and VKORC1).
Results: CYP2C19*2 (ORund=2.53, 95% CI [1.61-3.97], p<0.0001) and
ABCB1 TT3435 (ORund=2.01, 95% CI [1.22-3.30], p=0.006) carriers were
more frequent among patients with EST than controls while CYP2C19*17
(ORund=0.53, 95% CI [0.31-0.88], p=0.01) and ITGB3 PlA2 (ORund=0.50,
95% CI [0.29-0.87], p=0.01) carriers were less frequent. The accuracy of the
clinical model to discriminate between EST and controls (AUC 0.72, 95% CI
[0.66-0.77] did not differ significantly from the genetic model (AUC 0.68,
95% CI [0.62-0.73] (p=0.34), although combining both led to a significant
improvement in the discriminatory power of the model (AUC 0.78, 95% CI
[0.73-0.83], p=0.004). Among all independent predictors of early ST, the use
of high clopidogrel loading doses (OR=0.73, 95% CI[0.57-0.94], p=0.01) and
proton pump inhibitors (OR=2.19, 95% CI [1.28-3.72], p=0.004) were the
only modifiable factors.
Conclusion: In addition to established clinical and angiographic factors,
three genes involved in clopidogrel metabolism and platelet receptor function
(CYP2C19, ABCB1, ITGB3) were significantly significantly improved the
ability to predict early ST. PPI use and clopidogrel dose were both indepen-
dently correlated with the risk of early ST, suggesting that the final amount of
active metabolite generated is a major factor of prevention.
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Background: The impact of the timing of presentation of patients with
acute myocardial infarction (AMI) and the subsequent effect on management
and prognosis have not been fully investigated. 
Methods and results: A total of 1315 patients admitted for AMI between
January 1995 and December 2010 were included in our MonastIR AMI
(MIRAMI) registry. We deliberately excluded from the analysis patients who pre-
sented late and therefore did not receive a reperfusion strategy. A total of 768
patients did receive one of the two reperfusion strategies (thrombolysis or primary
angioplasty) and therefore were included in this analysis. There were no signifi-
cant differences on the frequency of AMI between the different periods of the day
and particularly between working and off-work hours. (p=0.92). Primary angio-
plasty was more frequently performed between 8 and 12 a.m (p=0.03). Thrombol-
ysis was more given between 8 and 12 p.m (p=0.03). AMI was more frequent
during winter (31.7% with p= 0.007) but mortality was higher during autumn
(p=0.008). There were no differences in mortality and heart failure according to
the hour of presentation (p=0.77 and p=0.44 respectively). 
Conclusion: The time of presentation of patients with AMI did have an
impact on the selection of the reperfusion strategy but not on the in-hospital
outcome. There is clearly an impact of the season with a higher in-hospital
mortality during autumn.
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Background: Carriers of the loss-of-function CYP2C19*2 genetic variant
have lower active metabolite levels and diminished platelet inhibition after
clopidogrel loading.
Objectives: To determine the pharmacokinetic (PK) and pharmacody-
namic (PD) responses to two LDs (LD) of clopidogrel according to carriage
of CYP2C19*2 genetic variant. 
Methods: Young post-MI patients heterozygous (wt/*2, n=43) or homo-
zygous (*2/*2, n=8) for the CYP2C19*2 genetic variant were matched with
patients not carrying the variant (wt/wt, n=58). All patients were randomized
to 300mg or 900mg clopidogrel LD. The relative reduction in residual platelet
aggregation (RR-RPA in %) and the area under the plasma concentration
(AUC0-6) – time curve of active metabolite) from baseline to six-hours post
loading were compared according to both LD and CYP2C19*2 carriage.
Results: The 300 mg LD led to a gene-dose effect for RR-RPA (–65.7±35.9%
in wt/wt vs. –48.0±38.4% in wt/*2 vs.-14.6±32.4% in *2/*2; overall p-
value=0.003, p=0.03 for wt/wt versus wt/*2, p=0.04 for wt/*2 versus *2/*2)
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